Washington links state health coverage decisions to Medicare and guidelines

The health technology review committee follows Medicare decisions and expert treatment guidelines when deciding coverage. The rule covers decisions about whether participating state health care programs cover reviewed medical treatments and technologies and what makes their use medically necessary. The committee may decide differently if its review finds substantial evidence about safety, effectiveness, and value for the money that supports that decision.

The Health Care Authority posts receipt of review submissions, and the committee completes its review and sends its decision to the person or organization that submitted the request. These requirements cover submissions for first reviews and repeat reviews of medical treatments and technologies. For an unfavorable decision, the committee must also send a written explanation of its reasons within 180 days of the initial submission. The posting deadline runs from receipt. The deadline to finish the review and send the decision runs from the initial submission.

The program administrator gives priority to medical treatments and technologies that meet the patient-access and review-need requirements. The administrator chooses treatments and technologies for review while consulting participating agencies and the review committee. Medicare or nationally recognized expert treatment guidelines must establish or recommend access for a patient group. There must also be safety, effectiveness, or value concerns, or wide differences in use; high actual or expected state spending; and enough evidence for a complete review.

The committee weighs new evidence in the context of earlier evidence during repeat reviews and examines all relevant published clinical trials for life-threatening or rare diseases. The disease-specific rule covers relevant trials published in medical journals that use expert review, including trials that assign treatments by chance. The administrator selects a repeat review when newly available evidence could change the earlier decision. For life-threatening or rare diseases, reviewers must consider applicable expert information explaining why a particular trial design would be unethical, impractical, or impossible for the patient group. Each coverage decision must be considered for a repeat review at least once every 18 months, beginning on the decision date.

An interested person or organization may petition the health technology review committee to review a treatment or technology. This route covers treatments and technologies the administrator has not otherwise selected for a first review or repeat review. The committee may select the requested treatment or technology for review; a petition does not guarantee a review.